期刊文献+

奈达铂联合5-Fu治疗头颈部肿瘤5例护理体会 被引量:5

Nursing experience of 5 cases of head and neck cancer treated with Nedaplatin combined with 5-Fu
下载PDF
导出
摘要 目的通过对5例头颈部肿瘤化疗患者的护理,提高患者的生存质量。方法针对患者肿瘤的特殊性和共同特点,予相应的心理护理、用药过程护理、化疗药物毒副作用的护理、饮食护理、口腔护理和健康教育。结果 1例鼻咽癌患者化疗后出现Ⅱ度骨髓抑制,予重组集落细胞刺激因子150μg皮下注射,24 h后复查血常规,白细胞上升;5例患者情绪稳定,善于沟通,达到良好的治疗效果。结论奈达铂治疗指数高,毒副作用相比顺铂小,减轻了患者精神压力和对化疗的恐惧感,同时加强了口腔局部并发症的护理,改变了不良卫生习惯,消除口腔异味,增加了患者的自信心,提高了患者的生存质量。 Objective To improve life quality of chemotherapy patients by summarizing nursing experience of 5 head and neck cancer cases. Methods According to the special features and common characteristics of five patients, the appropriate psychological care, the medication process care, side effects care, diet care, oral care and health education were performed. Results H degree bone marrow suppression appeared in one nasopharyngeal carcinoma patient after chemotherapy. The white blood cells increased 24 hours after the injection of 150μg re - colony stimulating factor. Five patients had emotional stability and willing to communication. Good therapeutic effect was achieved. Conclusion Compared with Cisplatin, Nedaplatin has a higher therapeutic effect and lower toxicity. It can reduce stress and fear of patients to chemotherapy, strengthening the nursing of local oral complications, changing bad health habits, eliminating mouth odor, increasing the pa- tients' self- confidence and improving their life quality.
作者 邵青伟
出处 《实用临床医药杂志》 CAS 2012年第2期1-2,5,共3页 Journal of Clinical Medicine in Practice
关键词 奈达铂 5-FU 头颈部肿瘤 护理 Nedaplatin 5 - Fu head and neck cancer nursing
  • 相关文献

参考文献9

二级参考文献35

共引文献27

同被引文献49

  • 1冯英明,闵婕,李刚,张贺龙,姬统理,宋扬,马宁强,王红玫.甲孕酮改善中晚期恶性肿瘤营养状况的临床观察[J].现代肿瘤医学,2004,12(6):544-547. 被引量:8
  • 2孙蕊,陈明远,孙健,张颖,张昌卿,侯景辉,洪明晃.TGF-β1及其信号通路分子在鼻咽癌中的表达及其临床意义[J].癌症,2007,26(9):1005-1009. 被引量:8
  • 3Wharton K, Derynck R. TGFbeta family signaling: novel insights in developmentand disease[J]. Development, 2009, 136: 3691-7.
  • 4Huang YS, Li BG, Qian J, et al. TGF-131 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25, 996 subjects [J]. Breast Cancer Res Treat, 2010, 123: 863-8.
  • 5Angenete E, Langenskiold M, Palmgren I, et al. Transforming growth factor beta-1 in rectal tumour, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients[J]. Int J Colorectal Dis, 2007, 22: 1331-8.
  • 6Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-131 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-celllung cancer:a combined analysis from Beijing and Michigan [J]. Int J Radiat Oncol Biol Phys, 2009, 4(5): 1385-90.
  • 7Chert HW, Yc C, Lai YL, et al. Change of plasma transforming growth factor-131 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy [J]. Jpn J Clin Oncol, 2005, 35(8): 427-32.
  • 8Lundberg M, Saarilahti K, Makitie AA, et al. TGFβ1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis [J]. Oral Oncol, 2010, 46: 369-72.
  • 9Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy [J]. Int J Radiat Oncol Biol Phys, 1992, 23(2): 457-67.
  • 10Anscher MS, Marks LB, Shafman TD, et al. Risk of long-term complications after TFG-betal-guided very-high-dose thoracic radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2003, 56: 988-95.

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部